NASPGHAN member advocates on Capitol Hill asking lawmakers to protect pediatric GI patients from insurance company tactics like #FailFirst protocols and non-medical switching that delay or deny access to prescribed biologic therapy. Calling on Congress to pass the #SafeStepAct!
Happy Friday!!! Here is today's algorithm for Monday's fantastic @MondayNightIBD discussion by @KTCesa & @SCKimCHP on the cardiac manifestations of IBD. My take home point: keep your stethoscope handy :). @DCharabaty@Empoweringpts9#IBDalgorithm.
@doctorboletoh@MondayNightIBD @SCKimCHP @DCharabaty Interesting thought. Tofacitinib has been used in immune-mediated myocarditis with no increase in adverse CV outcomes in IBD pts seen
https://t.co/xOWPktaNDX
https://t.co/ho4BuKa9Nf
In pediatric Acute Covid myocarditis, pt have higher CRP, but prompt recovery of ❤️ function and 🔻adverse outcomes (including death) compared to covid unrelated myocarditis
https://t.co/8uI1Ou3o5n
@DCharabaty@SchairerIBDMD@MondayNightIBD @SCKimCHP @sabpeds@IBD_Houston@P_DeepakIBDMD Very true! Both peri- and myocarditis may develop independently of IBD activity. Some case of carditis also occur pre-IBD diagnosis. This adds to the difficulty of diagnosis/management in these cases!
https://t.co/4Pzj1FxdMq
@MondayNightIBD @SCKimCHP @DCharabaty Anakinra shown to reduce the risk of #recurrent pericarditis compared to placebo in RCT. No impact on #IBD inflammation. No case reports in the literature for #IBD EIM myocarditis or pericarditis
https://t.co/L4n8WZiUv1
@MondayNightIBD @SCKimCHP @DCharabaty Treatment of #EIM Myocarditis/Pericarditis based on the relief of symptoms, decreasing inflammation, and the prevention of recurrence. Steroids are most common first line treatment. NSAIDS used rarely, since often insufficient and associated with IBD flares.